Clinical Trial Update: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating BH-30643 in subjects with locally advanced or metastatic non-small cell lung cancer harboring EGFR and/or HER2 mutations i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BH-30643

Snippet

Sponsor: BlossomHill Therapeutics | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1, Phase 2 | Status: RECRUITING